NCT00071903

Brief Summary

This study will examine whether the tendency to have thrombosis, or the formation of blood clots inside blood vessels, has a role in the development of pseudotumor cerebri (PTC). PTC causes symptoms and signs of isolated elevated blood pressure in the cranium, or covering of the brain. The disorder can lead to significant, negative effects on the visual system. Increased pressure of the cerebrospinal fluid, that is, fluid around the brain, is a factor, but the cause of the disorder is not clear. There has been documentation of clustering of PTC within families. It suggests that potential genetic polymorphisms-abilities to take on different forms-may become evident after exposure to conditions known to trigger PTC. Thrombosis comes about by interactions between genetic and environmental or acquired factors, or both, resulting in a blood clot at a specific time and location. Because the disease occurs in episodes, the interaction of the genetic and nongenetic risk factors is important. Cystinosis is a recessive disorder caused by deposits of cystine within the lysosomes of cells-that is, sac-like cell parts that contain various enzymes. Involvement of the kidneys remains the primary characteristic, eventually leading to renal failure. Of all of the risk factors that make it easier for blood clotting, a high level of a substance called homocysteine is of particular interest. Too much homocysteine in blood plasma is a common finding in patients with kidney failure, and it has been recently identified as an independent risk factor for diseases of the blood vessels. Participants of all ages who meet the Dandy criteria for PTC may be eligible for this study. Pregnant women will be excluded. There will also be a control group of nephropathic cystinosis patients who do not have PTC. Participants will be asked to undergo the following tests and procedures:

  • Medical history.
  • Physical examination, to evaluate the eye and nervous systems.
  • Collection of blood for DNA and other tests.
  • Collection of cerebrospinal fluid, through a procedure called lumbar puncture or spinal tap. The evaluation of patients will generally last 3 to 4 days. For the collection of cerebrospinal fluid, the patient's skin on the back will be numbed with a local anesthetic. A special needle will be inserted into the back, and a small amount of the fluid will be drawn through the needle. There will be pain for a minute, although there can be a headache lasting 24 hours. Also, there may be bruising, local pain, bleeding, or infection where the needle enters. Patients may also have a magnetic resonance imaging scan of their head. During the MRI scan, patients will lie still on a table that slides in and out of a metal cylinder surrounded by a strong magnetic field. Patients will be able to communicate with the MRI staff at all times and may ask to be moved out of the machine at any time.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
18

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Oct 2003

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 30, 2003

Completed
4 days until next milestone

First Submitted

Initial submission to the registry

November 3, 2003

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 4, 2003

Completed
4.7 years until next milestone

Study Completion

Last participant's last visit for all outcomes

July 18, 2008

Completed
Last Updated

July 2, 2017

Status Verified

July 18, 2008

First QC Date

November 3, 2003

Last Update Submit

June 30, 2017

Conditions

Keywords

ThrombophiliaIdiopathic Intracranial HypertensionKidney InvolvementLysosomal Storage DisorderCystinePseudotumor CerebriSusceptibility to ThrombosisNephropathic CystinosisPTCIntracranial Hypertension

Eligibility Criteria

Age2 Years - 50 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • signs and symptoms related to increased intracranial pressure;
  • no localizing neurological signs with the exception of unilateral or bilateral sixth nerve palsy;
  • neuroimaging study showing no mass lesion or hydrocephalus;
  • elevated opening pressure with normal cerebrospinal fluid contents on lumbar puncture.
  • Nephropathic cystinosis patients of all ages who meet the Dandy criteria for PTC will be considered for the study.

You may not qualify if:

  • Pregnant patients will be excluded from the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, 20892, United States

Location

Related Publications (3)

  • Quattrone A, Gambardella A, Carbone AM, Oliveri RL, Lavano A, De Marco EV, Civitelli D, Bono F, Zappia M, Pardatscher K, DiMinno G. A hypofibrinolytic state in overweight patients with cerebral venous thrombosis and isolated intracranial hypertension. J Neurol. 1999 Nov;246(11):1086-9. doi: 10.1007/s004150050517.

    PMID: 10631643BACKGROUND
  • Martins AN. Resistance to drainage of cerebrospinal fluid: clinical measurement and significance. J Neurol Neurosurg Psychiatry. 1973 Apr;36(2):313-8. doi: 10.1136/jnnp.36.2.313.

    PMID: 4541080BACKGROUND
  • Calabrese VP, Selhorst JB, Harbison JW. CSF infusion test in pseudotumor cerebri. Trans Am Neurol Assoc. 1978;103:146-50. No abstract available.

    PMID: 757043BACKGROUND

MeSH Terms

Conditions

Pseudotumor CerebriCystinosisThrombophiliaLysosomal Storage DiseasesIntracranial Hypertension

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesMetabolism, Inborn ErrorsGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesMetabolic DiseasesNutritional and Metabolic DiseasesHematologic DiseasesHemic and Lymphatic Diseases

Study Design

Study Type
observational
Sponsor Type
NIH

Study Record Dates

First Submitted

November 3, 2003

First Posted

November 4, 2003

Study Start

October 30, 2003

Study Completion

July 18, 2008

Last Updated

July 2, 2017

Record last verified: 2008-07-18

Locations